"The current medical product development path is becoming increasingly challenging, inefficient & costly."
  "Pharmaceutical […] productivity appears to be declining at the same time that the costs to develop a small number of treatments are increasing."
  "A new medicinal compound entering Phase 1 testing […] is estimated to have only an 8 % chance of reaching the market. This reflects a worsening outlook from the historical success rate of about 14 %."
  "Similar trends have been observed at regulatory agencies worldwide."

 "Big drug companies are facing patent expirations on many blockbuster drugs over the next five to 10 years. Meanwhile, there has been a steady decline in the number of genuinely new drugs approved by the Food and Drug Administration."
 "Negotiations are heating up in Cambridge, on the West Coast, and in Europe, as pharmaceutical executives compete for the most promising molecules."
 "They are signing scores of cheaper pacts for the earliest discoveries, looking to get a toehold on technology that may or may not succeed in the future."

«	page 1/3	»
	1